



**Media Releases » Torrent Pharma records 44% growth in Net Profit and 27% in Revenues during Q1 13-14**

*July 26th, 2013*

Ahmedabad-based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th June, 2013. The Q1'13-14 revenues stood at Rs. 972 crores, up by 27% from Rs. 767 crores in the comparable quarter of last year.

During Q1, domestic formulation business recorded revenues of Rs. 312 crores, growing by 12%. International revenues grew by 28% to Rs. 539 crores. In the international operations, US business reported a growth of 43%, Europe 49%, Rest of the World, including Russia and CIS 23%. , while Brazil registered a degrowth of 2%.

Profit before Taxes for the quarter was Rs. 187 crores compared to Rs. 140 crores during the same period last year. Profit after Taxes for the quarter was Rs. 149 crores compared to Rs. 102 crores during the same period last year.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs. 3200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthroughs in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 580 scientists in the areas of drug discovery and development. Torrent's manufacturing plant at Chattral has a capacity to manufacture approx. 5,500 million tablets, capsules and vials and 45,000 kgs of Bulk Drugs/API. The facility has been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,300 million tablets and 350 million capsules. Manufacturing plant at Sikkim has a capacity to manufacture 3,900 million tablets per annum.

